Bristol-Myers, Aslan deal

Aslan said Bristol-Myers reacquired rights to develop and commercialize cancer compound ASLAN002 ( BMS-777607) in China, Australia, Korea, Taiwan and other Asian territories. Aslan is to receive $10 ...